-
Loading metrics
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage
- Akiyoshi Shimoda ,
-
Kazuhiro Murai ,
Contributed equally to this work with: Akiyoshi Shimoda, Kazuhiro Murai
Roles Conceptualization, Data curation, Formal analysis, Writing – original draft
Affiliation Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan
⨯ -
Hayato Hikita ,
Roles Conceptualization, Data curation, Formal analysis
* E-mail: hikita@gh.med.osaka-u.ac.jp
Affiliation Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan
⨯ -
Satoshi Minami,
Roles Data curation, Formal analysis
Affiliation Department of Genetics, The University of Osaka Graduate School of Medicine, Suita, Japan
⨯ - Takayuki Miyake,
- Shinji Kuriki,
- Emi Sometani,
- Jihyun Sung,
- Satoshi Shigeno,
- Yuichiro Higuchi,
- Kazuki Maesaka,
- Kumiko Shirai,
-
Yuki Tahata,
Roles Data curation, Formal analysis
Affiliation Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan
⨯ - Yoshinobu Saito,
- Takahiro Kodama,
- Takeshi Takahashi,
- Hiroshi Suemizu,
- [ ... ],
- Tetsuo Takehara
- [ view all ]
- [ view less ]
https://orcid.org/0000-0001-8634-2922
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage
- Akiyoshi Shimoda,
- Kazuhiro Murai,
- Hayato Hikita,
- Satoshi Minami,
- Takayuki Miyake,
- Shinji Kuriki,
- Emi Sometani,
- Jihyun Sung,
- Satoshi Shigeno,
- Yuichiro Higuchi
- Published: January 16, 2026
- https://doi.org/10.1371/journal.pone.0340023